-
M&A Activity in a Fragmented CDMO Market
While there has been a slowdown in M&A in the pharmaceutical industry, the contract services market remains highly fragmented and players large and small continue to enhance their competitiveness through inorganic growth.
PAP-Q1-18-NI-001 -
Creating Comprehensive Solutions through Laboratory Testing
Lack of effective management of the outbound distribution of clinical trial materials can negatively impact study outcomes.
PAP-Q1-18-CL-011 -
Artificial Intelligence in Biopharmaceutical Manufacturing
Artificial Intelligence (AI) has significant potential to change the healthcare industry, from the way patients receive treatments to the ways in which drugs are discovered and manufactured.
PAP-Q1-18-CL-011 -
Ensuring Confidence in Viral Vector Manufacturing
Cell and gene therapies are rapidly advancing to late-stage clinical trials and commercialization.
PAP-Q1-18-CL-012 -
Expanding U.S. Supply Options for Large-Volume Parenterals
With limited numbers of producers supplying large-volume parenterals (LVPs) to the US market, shortages can result when natural disasters or manufacturing problems interrupt production operations.
PAP-Q1-18-CL-013 -
Overcoming Challenges in the Complex Market for Clinical Trials and Clinical Logistics
Increasing complexity, evolving treatment strategies, advancing technologies, data security challenges and the growing focus on patient centricity are all impacting the way in which clinical trials are conducted.
PAP-Q1-18-CL-010 -
Facilitating Implementation and Customer Service with Offline Serialization
Even though the FDA has extended the deadline for compliance with unit serialization requirements, UPM Pharmaceuticals serialized its first commercial product in May 2017, well ahead of time.
PAP-Q1-18-CL-005 -
Driving Change in the Pharma Industry and Biotech One Relationship at a Time
Although small and medium-sized pharma and biotech companies are driving the growth of the industry, they often don’t receive the attention and assistance that are essential to their success.
PAP-Q1-18-CL-004 -
Why Business Continuity Management is Important for CDMOs
Members of the pharmaceutical industry have a responsibility to guarantee both the supply of high-quality medicines and the safety of their personnel.
PAP-Q1-18-CL-003 -
A New Landscape: M&A in the Discovery & Research Sector
The CRO market is condensing while experiencing rapid growth.
PAP-Q1-18-NI-002 -
Getting to the Finish Line
The industry’s accelerating development of biopharmaceuticals has put pressure on the supply chain to improve and modernize fill/finish operations.
PAP-Q1-18-NI-004 -
What’s Driving M&A Among Pharma Sponsors?
Companies are seeking access to new technologies, looking to expand their pipelines and therapeutic expertise and reach both new patient populations and geographies.
PAP-Q1-18-NI-003 -
Overcoming Formulation Challenges with Liquid-fill Capsules
Liquid-filled hard-shell capsules enable formulators to overcome issues with complex APIs, while also achieving improved efficacy and safety.
PAP-Q1-18-CL-004 -
Uniting the Industry for the Prevention of “Pharmageddon”
Revolutionary change is occurring in the pharmaceutical industry.
PAP-Q1-18-CL-001 -
Microbial and Biological Decontamination of Equipment Brings Peace of Mind
The ramifications of an adverse biological occurrence are higher in the pharmaceutical industry than in any other.
PAP-Q1-18-CL-002 -
Investing in New Technologies for Innovative Functional Solutions
Following a reorganization and finalization of its new growth strategy, SPI is re-engaging in innovation.
PAP-Q1-18-CL-009 -
Supporting Parenteral Development and Manufacturing with End-to-End Services
The manufacture of biologic drug products, particularly those that require aseptic processing, is quite complex and requires specialized expertise.
PAP-Q1-18-CL-014 -
Death to Cleanrooms in Biopharmaceutical Manufacturing
Recently, advances in the design, form, function and operation of bioprocessing equipment has made it possible to close — or functionally close — biological active ingredient (API) manufacturing operations.
PAP-Q1-18-CL-006 -
Meet Chemo CMO: Preferred Partner for Injectables Manufacturing
API sterilization is a unique capability, and particularly important for products formulated as suspensions.
PAP-Q1-18-CL-015 -
Fully Supporting Customer Needs for Biologics Development and Manufacturing
Over the past seven years, Samsung BioLogics has constructed three state-of-the-art production facilities offering end-to-end integrated services to support the rapidly expanding clinical and commercial needs of customers.
PAP-Q1-18-CL-016 -
Meeting the Need for Small-Volume API Manufacturing
As the pharmaceutical industry shifts its focus from blockbusters to targeted therapies, the demand for active pharmaceutical ingredient (API) manufacturing capabilities at the kilogram scale is increasing.
PAP-Q1-18-CL-016 -
Focused on Fermentation
Microbial fermentation continues to be an important upstream bioprocess for the production of conventional and next-generation biologics
PAP-Q1-18-CL-007 -
Leveraging Lyophilization Development Expertise for Clinical Manufacturing
Biopharmaceutical companies are increasingly relying on contract service providers with specialized lyophilization expertise and equipment.
PAP-Q1-18-CL-008 -
Q: What Role has M&A Played in your Company’s Growth?
How mergers and acquistions have made an impact.
PAP-Q4-17-RT-001 -
Q: How do you Address Operational Excellence as an Institution?
Planning for growth and flexibility at the operational level.
PAP-Q4-17-RT-002
-
Facilitating Implementation and Customer Service with Offline Serialization
Tyler Ewald, Associate Director, Manufacturing and Joseph Quales, Supervisor, Label Control at UPM Pharmaceuticals explain the company’s offline serialization system.
-
Successful Solid Dose Equipment Training
Helping operators become technicians and building strong production teams requires training on machine set up, operation, cleaning, and maintenance, explains Mike Tousey, Technical Director/CEO of Techceuticals.
-
Artificial Intelligence in Biopharmaceutical Manufacturing
Constantin Loghinov, Managing Director, Machine Intelligence for Life Sciences, MILS Group LLC explains how AI has the power to change the healthcare industry.
-
What’s Driving M&A Among Pharma Sponsors?
Merger and acquisition activity is, overall, driven by a need to improve competitiveness.
-
Moving Quality to the Forefront Brings Measurable Results
Chris Curtin, Executive Vice President and Chief Operating Officer of UPM Pharmaceuticals explains the implementation of Manufacturing Quality Assurance (MQA).
-
Segregation in the Design of Gene Therapy Manufacturing Facilities
Peter Walters, Lead Process Engineer for CRB USA explains segregating manufacturing operations.
-
WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services
WuXi AppTec has announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey.
-
Robotic Microscope Used for Brain Surgery
The robotic technology was originally used on the International Space Station.
-
New Lung Cancer Treatment Awarded Priority Review by FDA
Pfizer’s dacomitinib is being reviewed as a first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR-activating mutations.
-
Merck’s KEYTRUDA®(pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent
KEYTRUDA is First Anti-PD-1 Therapy to Show Recurrence-Free Survival (RFS) Benefit Across Stage IIIA (> 1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma.
-
Uniting the Industry for the Prevention of “Pharmageddon”
Tim Tyson Chairman and CEO of Avara Pharmaceutical Services explains Pharmageddon and how to prevent it.
-
Overcoming Formulation Challenges with Liquid-fill Capsules
Eli Elias, Director of Business Development for CapsCanada discusses how liquid-filled hard-shell capsules enable formulators to overcome challenges with complex API.
-
Leveraging Lyophilization Development Expertise for Clinical Manufacturing
By late 2018, AB BioTechnologies, Inc.will be providing cGMP manufacturing of Phase I-III clinical trial material and small-volume commercial products, says Jeff Schwegman, Founder & CEO.
-
Supporting Parenteral Development and Manufacturing with End-to-End Services
Oskar Gold, Senior Vice President of Key Account Management and Marketing/Corporate Communications for Vetter, explains leveraging end-to-end support.
-
M&A Activity in a Fragmented CDMO Market
While there has been a slowdown in M&A in the pharmaceutical industry, the contract services market remains highly fragmented and players large and small continue to enhance their competitiveness through inorganic growth.
-
From Digitalization to Nanoscale Delivery: Emerging Technologies Are Driving the Future of Pharma
The (bio)pharmaceutical industry is becoming a high-technology sector with success directly linked to innovation.
-
Marken Announces Plans To Add Nursing Services To Home-Based Trials
Marken has announced their plans to develop a global home-based nursing network to supplement Marken's existing Direct to/from Patient (DTP/DFP) services.
-
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion
Oncology business provides Servier S.A.S. with an immediate presence in the U.S., enhancing its commitment to addressing unmet patient needs in oncology.
-
FDA Finalizes Guidances to Accelerate the Development of Reliable, Beneficial Next Generation Sequencing-Based Tests
The agency is leveraging new tools and policies to advance the creation of innovative genetic and genomic-based tests and help ensure the validity of their results.
-
Charles River Laboratories to Expand Partnership with PathoQuest
Charles River Laboratories (CRL) and PathoQuest have announced the expansion of their strategic biologics partnerships, giving CRL further access to PathoQuest’s next-generation sequencing services.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestSyros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer
Apr 19, 2018 7:35:00 AM PR-M04-18-NI-67City of Hope Certified to Provide First FDA-Approved CAR T Cell Therapy for Pediatric and Young Adult Patients
Apr 19, 2018 7:30:00 AM PR-M04-18-NI-68Immunotherapy Prior to Surgery Shows Promise in Fight Against Lung Cancer
Apr 17, 2018 12:02:35 PM PAO-M04-18-NI-016Pfizer and Allogene Therapeutics Form Alliance, Further Developing CAR-T Therapy
Apr 17, 2018 11:55:12 AM PAO-M04-18-NI-015United Neuroscience Ltd. and Boston University Lee Goldstein Laboratory Enter Collaboration, Targeting Treatment and Prevention of Chronic Traumatic Encephalopathy (CTE)
Apr 17, 2018 11:34:04 AM PAO-M04-18-NI-012Charles River Laboratories to Expand Partnership with PathoQuest
Apr 17, 2018 11:29:36 AM PAO-M04-18-NI-011Sysmex Inostics Expands OncoBEAM™ Liquid Biopsy Testing in the U.S. to Assist Clinicians and Patients
Apr 17, 2018 7:45:00 AM PR-M04-18-NI-57GSK to Take Over Full Ownership of Consumer Healthcare JV with Novartis
Apr 12, 2018 10:12:12 AM PAO-M04-18-NI-008Compugen, MedImmune to Collaborate on Bi- and Multi-Specific Antibodies
Apr 12, 2018 10:08:21 AM PAO-M04-18-NI-007
TOPICS
View All TopicsPRESS RELEASES
View All-
WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services
Apr 19, 2018 1:21:37 PM -
Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford
Apr 18, 2018 7:50:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
